Roche Pharmaceutical Development and Sales Overview

YTD Sep 2022: Portfolio rejuvenation ongoing CHFM 46'684 +2% at CER -383 +2'397 -612 +217 -1,460 +621 -427 47'037 YTD Sep 2021 Dia base business Dia Pharma Ronapreve Actemra COVID-19 underlying sales sales sales business AHR erosion1 Fx YTD Sep 2022 YTD Sep 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion Diversification of Roche business YTD Sep 2017 CHF 39.4bn YTD Sep 2022 CHF 47.0bn AHR AHR Diagnostics Other pharma Ophthalmology Infectious diseases Immunology Oncology AHR Neuroscience Hemophilia A Roche 9

View entire presentation